{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:34:47Z","timestamp":1791308087221,"version":"4.3.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,6,30]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Vaccination against influenza, with and without the adjuvant MF59, decreases the risk of inhibitor development in HA mice. Decreased FVIII immunogenicity may be attributed to antigenic competition via T-cell chemotaxis toward the site of vaccination.<\/jats:p>","DOI":"10.1182\/blood-2015-11-679282","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T03:59:04Z","timestamp":1459483144000},"page":"3439-3449","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A"],"prefix":"10.1182","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2916-2954","authenticated-orcid":false,"given":"Jesse D.","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Pathology & Molecular Medicine, Queen\u2019s University, Kingston, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8711-0445","authenticated-orcid":false,"given":"Paul C.","family":"Moorehead","sequence":"additional","affiliation":[{"name":"Discipline of Pediatrics, Faculty of Medicine, Memorial University, St. John\u2019s, NL, Canada;"},{"name":"Section of Pediatric Hematology\/Oncology, Janeway Children\u2019s Health and Rehabilitation Centre, St. John\u2019s, NL, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Sponagle","sequence":"additional","affiliation":[{"name":"Department of Pathology & Molecular Medicine, Queen\u2019s University, Kingston, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina N.","family":"Steinitz","sequence":"additional","affiliation":[{"name":"Baxalta Innovation GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit M.","family":"Reipert","sequence":"additional","affiliation":[{"name":"Baxalta Innovation GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hough","sequence":"additional","affiliation":[{"name":"Department of Pathology & Molecular Medicine, Queen\u2019s University, Kingston, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[{"name":"Department of Pathology & Molecular Medicine, Queen\u2019s University, Kingston, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8044","key":"2019111904445842500_B1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.","volume":"310","author":"Brackmann","year":"1977","journal-title":"Lancet"},{"issue":"suppl 1","key":"2019111904445842500_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations.","volume":"13","author":"DiMichele","year":"2007","journal-title":"Haemophilia"},{"issue":"20","key":"2019111904445842500_B3","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111904445842500_B4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review.","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"1","key":"2019111904445842500_B5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jth.12065","article-title":"Dangerous liaisons: how the immune system deals with factor VIII.","volume":"11","author":"Wroblewska","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111904445842500_B6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2011.10.001","article-title":"Requirements for immune recognition and processing of factor VIII by antigen-presenting cells.","volume":"26","author":"van Haren","year":"2012","journal-title":"Blood Rev"},{"issue":"5566","key":"2019111904445842500_B7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self.","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"issue":"3","key":"2019111904445842500_B8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1160\/TH05-11-0729","article-title":"Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.","volume":"96","author":"Pfistershammer","year":"2006","journal-title":"Thromb Haemost"},{"issue":"21","key":"2019111904445842500_B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.627.627","article-title":"Surgical injury alone does not provoke the development of factor VIII inhibitors in mouse models of hemophilia A [abstract].","volume":"120","author":"Moorehead","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111904445842500_B10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1542\/peds.2013-3965","article-title":"Recommended childhood and adolescent immunization schedule--United States, 2014.","volume":"133","author":"Committee on Infectious Diseases, American Academy of Pediatrics","year":"2014","journal-title":"Pediatrics"},{"issue":"17","key":"2019111904445842500_B11","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/blood-2011-08-374645","article-title":"CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.","volume":"119","author":"Steinitz","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111904445842500_B12","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1111\/j.1365-2516.2012.02872.x","article-title":"Allergenic vaccines administration and inhibitor development in haemophilia.","volume":"18","author":"Bermejo","year":"2012","journal-title":"Haemophilia"},{"issue":"4","key":"2019111904445842500_B13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood-2008-09-174649","article-title":"Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.","volume":"114","author":"Qadura","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111904445842500_B14","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.vaccine.2009.11.054","article-title":"Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.","volume":"28","author":"Lum","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"2019111904445842500_B15","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.vaccine.2008.12.038","article-title":"No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine.","volume":"27","author":"Stowe","year":"2009","journal-title":"Vaccine"},{"issue":"20","key":"2019111904445842500_B16","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1016\/j.vaccine.2006.03.003","article-title":"\u2018Combined vaccines are like a sudden onslaught to the body\u2019s immune system\u2019: parental concerns about vaccine \u2018overload\u2019 and \u2018immune-vulnerability\u2019.","volume":"24","author":"Hilton","year":"2006","journal-title":"Vaccine"},{"issue":"suppl 1","key":"2019111904445842500_B17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2009.03403.x","article-title":"Opportunities and limitations of mouse models humanized for HLA class II antigens.","volume":"7","author":"Reipert","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111904445842500_B18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"issue":"10","key":"2019111904445842500_B19","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","article-title":"High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.","volume":"106","author":"Hausl","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111904445842500_B20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111904445842500_B21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1538-7836.2012.04705.x","article-title":"Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.","volume":"10","author":"Miller","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111904445842500_B22","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1538-7836.2009.03571.x","article-title":"Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.","volume":"7","author":"Navarrete","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2019111904445842500_B23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1538-7836.2009.03437.x","article-title":"Clinical prediction models for inhibitor development in severe hemophilia A.","volume":"7","author":"van den Berg","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111904445842500_B24","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"5663","key":"2019111904445842500_B25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"issue":"1","key":"2019111904445842500_B26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2010-06-289009","article-title":"Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9.","volume":"117","author":"Allacher","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111904445842500_B27","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.","volume":"153","author":"Valensi","year":"1994","journal-title":"J Immunol"},{"issue":"2","key":"2019111904445842500_B28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2516.2010.02397.x","article-title":"Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb\/c and C57BL\/6 haemophilia A mice.","volume":"17","author":"Qadura","year":"2011","journal-title":"Haemophilia"},{"issue":"6","key":"2019111904445842500_B29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.clpt.6100402","article-title":"MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?","volume":"82","author":"O\u2019Hagan","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2019111904445842500_B30","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.4049\/jimmunol.1400623","article-title":"Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells.","volume":"194","author":"Cantisani","year":"2015","journal-title":"J Immunol"},{"issue":"8","key":"2019111904445842500_B31","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells.","volume":"180","author":"Seubert","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"2019111904445842500_B32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"issue":"10","key":"2019111904445842500_B33","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/nm.3958","article-title":"Endogenous antigen processing drives the primary CD4+ T cell response to influenza.","volume":"21","author":"Miller","year":"2015","journal-title":"Nat Med"},{"issue":"suppl 2","key":"2019111904445842500_B34","first-page":"147","article-title":"Do vaccinations influence the risk of inhibitor development in patients with severe hemophilia A? [abstract].","volume":"13","author":"Hashemi","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111904445842500_B35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis.","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111904445842500_B36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1201248","article-title":"Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.","volume":"367","author":"Reshef","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/26\/3439\/1394687\/3439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/26\/3439\/1394687\/3439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T11:54:26Z","timestamp":1718452466000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/26\/3439\/35367\/Concurrent-influenza-vaccination-reduces-antiFVIII"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":36,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-11-679282","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}